Table of Content


Introduction
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Development
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Therapeutics Assessment
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Companies Involved in Therapeutics Development
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Drug Profiles
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Gamma Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Gamma or Phosphoinositide 3 Kise Catalytic Gamma Polypeptide or Serine/Threonine Protein Kise PIK3CG or p120 PI3K or PIK3CG or EC 2.7.11.1 or EC 2.7.1.153) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Applied Therapeutics Inc, H1 2020
Pipeline by Arcus Biosciences Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by BioMed Valley Discoveries Inc, H1 2020
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Hutchison MediPharma Ltd, H1 2020
Pipeline by Infinity Pharmaceuticals Inc, H1 2020
Pipeline by Kither Biotech Srl, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by PIQUR Therapeutics AG, H1 2020
Pipeline by Rhizen Pharmaceuticals SA, H1 2020
Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H1 2020
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
Pipeline by Sphaera Pharma Pte Ltd, H1 2020
Pipeline by Verastem Inc, H1 2020
Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020